M. S. Czuczman - Concepedia

Author

M. S. Czuczman

Roswell Park Comprehensive Cancer Center

Also Known As

M CZUCZMAN, M Czuczman, M S Czuczman, M. Czuczman, M. S. Czuczman, M.S. Czuczman, MS Czuczman

Publications

7.3K

Citations

H-Index

Concepts

All Affiliations

Roswell Park Comprehensive Cancer Center Mayo Clinic in Arizona The University of Texas MD Anderson Cancer Center Mayo Clinic WinnMed

About

M. S. Czuczman is an author at Roswell Park Comprehensive Cancer Center specializing in medicine, immunology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	24	2.3K
2	Health Sciences	9	9	336
3	Blood Transplantation	3	3	134
4	Cellular Therapies	2	2	65
5	Hepatology	1	1	84

M. S. Czuczman

Publications

7.1K

Citations

H-Index

Page 1

	Year	Citations
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Peter McLaughlin, A.J. Grillo-López, Brian K. Link, Journal of Clinical Oncology	1998	2.8K
Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy M. S. Czuczman, A.J. Grillo-López, Christine A. White, Journal of Clinical Oncology	1999	855
Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma Neil L. Berinstein, A.J. Grillo-López, Christine A. White, Annals of Oncology Anti-tumor ResponseLymphoid NeoplasiaHematological MalignancySerum RituximabMedicine	1998	520
Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin’s Lymphoma Julie M. Vose, Brian K. Link, Michael L. Grossbard, Journal of Clinical Oncology	2001	416
An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma Thomas E. Witzig, Julie M. Vose, Pier Luigi Zinzani, Annals of Oncology Hematological MalignancyLymphoid NeoplasiaSingle-agent LenalidomideMedicineImmunology	2011	392
Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma Lawrence D. Piro, Christine A. White, A.J. Grillo-López, Annals of Oncology Lymphoid NeoplasiaMedicineImmunologyAnti-cd20 Monoclonal AntibodyImmune Checkpoint Inhibitor	1999	368
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype Wyndham H. Wilson, Sin‐Ho Jung, Pierluigi Porcu, Haematologica	2011	165
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes Matthias Pfeifer, Bing Zheng, Tabea Erdmann, Leukemia Lymphoid NeoplasiaMalignant Blood DisorderImmunologyPathologyAutoimmunity	2015	149
Rituximab in Combination With Fludarabine Chemotherapy in Low-Grade or Follicular Lymphoma M. S. Czuczman, Alexandra Koryzna, Alice Mohr, Journal of Clinical Oncology	2005	144
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma Anas Younes, Julie M. Vose, Andrew D. Zelenetz, British Journal of Cancer	2010	129

Page 1